美国 · 平台与数据 · MarketBeat
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following…
在 MarketBeat 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)
